ATE292983T1 - Chimäres retrovirus/adenovirus system - Google Patents

Chimäres retrovirus/adenovirus system

Info

Publication number
ATE292983T1
ATE292983T1 AT97948396T AT97948396T ATE292983T1 AT E292983 T1 ATE292983 T1 AT E292983T1 AT 97948396 T AT97948396 T AT 97948396T AT 97948396 T AT97948396 T AT 97948396T AT E292983 T1 ATE292983 T1 AT E292983T1
Authority
AT
Austria
Prior art keywords
retroviral
vector
functions
chimeric
cells
Prior art date
Application number
AT97948396T
Other languages
English (en)
Inventor
David T Curiel
Original Assignee
Univ Alabama Birmingham Res Fo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alabama Birmingham Res Fo filed Critical Univ Alabama Birmingham Res Fo
Application granted granted Critical
Publication of ATE292983T1 publication Critical patent/ATE292983T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT97948396T 1996-11-19 1997-11-19 Chimäres retrovirus/adenovirus system ATE292983T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3132396P 1996-11-19 1996-11-19
US3708197P 1997-02-04 1997-02-04
PCT/US1997/021169 WO1998022143A1 (en) 1996-11-19 1997-11-19 Chimeric retrovirus/adenovirus system

Publications (1)

Publication Number Publication Date
ATE292983T1 true ATE292983T1 (de) 2005-04-15

Family

ID=26707084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97948396T ATE292983T1 (de) 1996-11-19 1997-11-19 Chimäres retrovirus/adenovirus system

Country Status (8)

Country Link
US (1) US6333030B1 (de)
EP (1) EP0956052B1 (de)
JP (1) JP4214239B2 (de)
AT (1) ATE292983T1 (de)
AU (1) AU728610B2 (de)
CA (1) CA2272121A1 (de)
DE (1) DE69733035T2 (de)
WO (1) WO1998022143A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
ES2256842T4 (es) * 1993-10-25 2007-02-01 Canji, Inc. Vector de adenovirus recombinante y metodos de uso.
US20060275261A1 (en) * 1993-10-25 2006-12-07 Canji, Inc. Adenoviral vectors having a protein IX deletion
US20010006629A1 (en) * 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
WO1998042856A1 (en) * 1997-03-21 1998-10-01 Enzo Therapeutics, Inc., A Fully Owned Subsidiary Of Enzo Biochem, Inc. Vectors and viral vectors, and packaging cell lines for propagating same
US8703480B1 (en) 1997-03-21 2014-04-22 Enzo Therapeutics, Inc. Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells
WO1998046778A1 (en) * 1997-04-11 1998-10-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Transgenomic viruses and the use thereof
WO1999044423A1 (en) * 1998-03-03 1999-09-10 The Uab Research Foundation Amplification of gene transfer and gene therapy by controlled replication
US20060183228A1 (en) * 1998-03-24 2006-08-17 Enzo Therapeutics, Inc. Viral vectors with surface or envelope components
FR2778670B1 (fr) * 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa Methodes et compositions pour la production de particules virales
WO2000017376A1 (en) * 1998-09-22 2000-03-30 The Governement Of The United States Of America, As Represented By The Secretary Of The Departement Of Health And Human Services Replication deficient retroviral vector system and methods of using
AU2001233132A1 (en) * 2000-01-31 2001-08-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Hybrid adeno-retroviral vector for the transfection of cells
WO2001092550A2 (en) * 2000-05-31 2001-12-06 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
WO2002061104A2 (en) 2001-01-30 2002-08-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Hybrid adenoviral vector
US7271150B2 (en) 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20040086485A1 (en) * 2001-10-04 2004-05-06 Aguilar-Cordova Carlos Estuardo Chemeric viral vectors for gene therapy
US20070037284A1 (en) * 2003-06-04 2007-02-15 Enzo Therapeutics, Inc. Vectors for expressing exogenous gene or exogenous nucleic acid sequences
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
US20230348557A1 (en) 2020-02-06 2023-11-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education T cell receptors Targeting Defective DNA Repair Proteins
US10822379B1 (en) 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2239366A1 (en) * 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors

Also Published As

Publication number Publication date
EP0956052B1 (de) 2005-04-13
EP0956052A1 (de) 1999-11-17
DE69733035D1 (en) 2005-05-19
JP2001509009A (ja) 2001-07-10
WO1998022143A1 (en) 1998-05-28
AU728610B2 (en) 2001-01-11
AU5447598A (en) 1998-06-10
US6333030B1 (en) 2001-12-25
CA2272121A1 (en) 1998-05-28
JP4214239B2 (ja) 2009-01-28
EP0956052A4 (de) 2001-05-02
DE69733035T2 (de) 2005-11-24

Similar Documents

Publication Publication Date Title
ATE292983T1 (de) Chimäres retrovirus/adenovirus system
Feng et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector
AU737801B2 (en) Lentiviral vectors
US6323031B1 (en) Lentiviral vectors derived from SIVagm, methods for their preparation and their use for gene transfer into mammalian cells
US6761884B1 (en) Vectors including foreign genes and negative selective markers
US7303910B2 (en) Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
Romano et al. Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications
NZ500740A (en) Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
EP1076715A1 (de) Lentivirale Verpackungszellen
Pizzato et al. Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer
Shinkuma Advances in gene therapy and their application to skin diseases: A review
EP1244797A4 (de) Fusionsprotein verabreichungssystem und dessen verwendungen
US20020034393A1 (en) Vector
US20080124308A1 (en) Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped With Arenavirus Glycoproteins
AU758155B2 (en) Construction of retroviral producer cells from adenoviral and retroviral vectors
ATE226638T1 (de) Retroviraler vektor und dessen verwendung in gentherapie
Zhao‐Emonet et al. T Cell‐specific expression from Mo‐MLV retroviral vectors containing a CD4 mini‐promoter/enhancer
KR20020003215A (ko) 기능성 및 비기능성 스플라이스 도너와 스플라이스 억셉터사이트로 구성된 레트로바이러스 벡터
US6130089A (en) Materials and methods for gene transfer
Blomberg et al. Gene therapy of monogenic and cardiovascular disorders
Gibson et al. Delivery of tumor suppressor genes to reverse the malignant phenotype
Suzuki et al. Infection of human cells by murine ecotropic viruses: retroviral vectors carrying the hygromycin resistance-encoding gene
Sedlacek et al. Somatic Gene Therapy
Baum et al. Retroviral Transfer and Expression of Drug Resistance Genes in Hematopoietic Cells
Chowdhury et al. Efficient retrovirus targeting of CEA-positive tumours

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties